Safety and efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE)

被引：0
|
作者：
Kozloff, M.
Hainsworth, J.
Badrinath, S.
Cohn, A.
Flynn, P.
Steis, R.
Dong, W.
Suzuki, S.
Sarkar, S.
Sugrue, M.
Grothey, A.
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Genentech Inc, San Francisco, CA 94080 USA
[3] Atlanta Canc Care, Roswell, GA USA
[4] Abbott NW Hosp, Minneapolis, MN USA
[5] Rocky Mt Canc Ctr, Denver, CO USA
[6] Florida Oncol Associates, Jacksonville, FL USA
[7] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[8] Univ Chicago, Chicago, IL 60637 USA
[9] Ingalls Hosp, Harvey, IL USA
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：24 / 24
页数：1
相关论文
共 50 条
  • [21] Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): Preliminary results from a larger registry in the US
    Kozloff, M
    Cohn, A
    Christiansen, N
    Flynn, P
    Kabbinavar, F
    Robles, R
    Yood, MU
    Sarkar, S
    Hambleton, J
    Grothey, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 262S - 262S
  • [22] Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer
    Vaidyanathan, Gayatri
    Groman, Adrienne
    Wilding, Gregory
    Fakih, Marwan G.
    ONCOLOGY, 2010, 79 (1-2) : 67 - 71
  • [23] Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT
    Berry, S. R.
    Van Cutsem, E.
    Kretzschmar, A.
    Michael, M.
    Rivera, F.
    DiBartolomeo, M.
    Mazier, M. A.
    Andre, N.
    Cunningham, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ubago, R.
    Castillo, M. A.
    Flores, S.
    Beltran, C.
    VALUE IN HEALTH, 2011, 14 (07) : A435 - A435
  • [25] Prognostic factors of metastatic colorectal cancer patients undergoing first-line chemotherapy plus bevacizumab
    Bousahba, A.
    Behourah, Z.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] Optimizing the Efficacy of First-Line Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer Analysis of Multiple Methods
    Li, Shaotang
    Chi, Pan
    BIODRUGS, 2011, 25 (01) : 43 - 50
  • [27] The study of efficacy and safety of chemotherapy plus bevacizumab with oxaliplatin stop-and-go strategy in first-line treatment for metastatic colorectal cancer.
    Takano, Nao
    Nakayama, Goro
    Kodera, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [28] EFFICACY OF BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY WITH IRINOTECAN AND CAPECITABINE (XELIRI) IN FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ocvirk, J.
    Rebersek, M.
    Boc, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 129 - 129
  • [29] Safety and efficacy of first-line chemotherapy in unresected metastatic colorectal cancer
    Puthillath, Ajithkumar
    Dunn, Kelli Bullard
    Rajput, Ashwani
    Smith, Judy
    Yang, Gary
    Wilding, Gregory E.
    Tan, Wei
    Gupta, Bhavna
    Fakih, Marwan G.
    CLINICAL COLORECTAL CANCER, 2007, 6 (10) : 710 - 715
  • [30] Efficacy and safety of bevacizumab in combination with irinotecan and capecitabine in first-line treatment of metastatic colorectal cancer
    Jungic, Sasa
    Tubic, Biljana
    Gajanin, Radoslav
    Gojkovic, Zdenka
    Rakita, Ivanka
    VOJNOSANITETSKI PREGLED, 2017, 74 (03) : 249 - 255
12345